{"id":"dendritic-cell-immunotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Flu-like symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dendritic cells are harvested from the patient, cultured ex vivo, and loaded with tumor-associated antigens or engineered to express tumor antigens. These activated dendritic cells are then reinfused to prime and expand tumor-specific CD8+ T cells and CD4+ helper T cells, generating a durable anti-tumor immune response. This approach harnesses the body's adaptive immune system to recognize and eliminate malignant cells.","oneSentence":"Dendritic cell immunotherapy activates the patient's own dendritic cells to present tumor antigens and stimulate a cytotoxic T-cell response against cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:09:00.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication not publicly detailed for this investigational product)"}]},"trialDetails":[{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":"Breast Cancer, Breast Cancer Female, Breast Cancer, Male","enrollment":31},{"nctId":"NCT04801147","phase":"PHASE1, PHASE2","title":"Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2010-06-26","conditions":"Glioblastoma","enrollment":76},{"nctId":"NCT06418724","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2026-07-30","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT06805305","phase":"PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2025-03-17","conditions":"Glioblastoma (GBM)","enrollment":180},{"nctId":"NCT04837547","phase":"PHASE1","title":"PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2021-09-20","conditions":"Neuroblastoma, Diffuse Intrinsic Pontine Glioma","enrollment":24},{"nctId":"NCT03384914","phase":"PHASE2","title":"Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-02-19","conditions":"Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I","enrollment":119},{"nctId":"NCT05806814","phase":"PHASE1","title":"Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2023-11-12","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":13},{"nctId":"NCT04335890","phase":"PHASE1","title":"IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma","status":"COMPLETED","sponsor":"Hasumi International Research Foundation","startDate":"2020-09-24","conditions":"Melanoma, Uveal Metastatic","enrollment":17},{"nctId":"NCT06253494","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-14","conditions":"Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium","enrollment":60},{"nctId":"NCT04969887","phase":"PHASE2","title":"Combination Immunotherapy in Rare Cancers Under InvesTigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2021-08-03","conditions":"Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm","enrollment":240},{"nctId":"NCT07288112","phase":"PHASE1, PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2026-02-23","conditions":"Refractory Melanoma","enrollment":35},{"nctId":"NCT02063724","phase":"PHASE1","title":"HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2014-10-01","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT05799612","phase":"PHASE1","title":"Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-22","conditions":"Angiosarcoma","enrollment":""},{"nctId":"NCT07384897","phase":"NA","title":"Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease","status":"RECRUITING","sponsor":"Université Catholique de Louvain","startDate":"2025-02-17","conditions":"Lung Cancer (Diagnosis), Sarcoidosis, Chronic Obstructive Pulmonary Disease","enrollment":425},{"nctId":"NCT03334305","phase":"PHASE1","title":"Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-05-16","conditions":"Malignant Glioma, High Grade Glioma","enrollment":18},{"nctId":"NCT07374029","phase":"PHASE1","title":"Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":30},{"nctId":"NCT04590872","phase":"PHASE1","title":"An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-06-16","conditions":"Type 1 Diabetes Mellitus","enrollment":6},{"nctId":"NCT06765876","phase":"EARLY_PHASE1","title":"CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial","status":"RECRUITING","sponsor":"Institute of Hematology and Blood Transfusion, Czech Republic","startDate":"2024-10-23","conditions":"Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic Syndromes (MDS)","enrollment":18},{"nctId":"NCT05378464","phase":"PHASE1","title":"Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-05-31","conditions":"HER2-positive Breast Cancer","enrollment":28},{"nctId":"NCT07317154","phase":"PHASE1","title":"Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01","conditions":"Recurrent Respiratory Papillomatosis","enrollment":9},{"nctId":"NCT06866158","phase":"PHASE1, PHASE2","title":"Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"PT. JES Kasih Nusantara Sejahterah","startDate":"2024-05-01","conditions":"Diabetic Kidney Disease (DKD)","enrollment":80},{"nctId":"NCT04373031","phase":"PHASE2","title":"Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2020-12-30","conditions":"Breast Cancer, Breast Neoplasms","enrollment":12},{"nctId":"NCT05773859","phase":"PHASE1, PHASE2","title":"NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2023-03-17","conditions":"Epithelial Ovarian Cancer, Ovarian Carcinoma","enrollment":10},{"nctId":"NCT06100705","phase":"PHASE2","title":"Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-12-20","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":26},{"nctId":"NCT03396575","phase":"PHASE1","title":"Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-07-17","conditions":"Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma","enrollment":11},{"nctId":"NCT06296056","phase":"PHASE1","title":"Phase I Trial of Combined Immune Cell Therapy for Metastatic Stage IV Solid Tumors (SDH-Combi)","status":"COMPLETED","sponsor":"Seoul Hospital","startDate":"2024-08-01","conditions":"Solid Tumors, Metastatic","enrollment":9},{"nctId":"NCT07090174","phase":"PHASE2","title":"Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV","status":"NOT_YET_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-10-20","conditions":"HPV Associated Cancers, HIV (Human Immunodeficiency Virus), Anal Cancer","enrollment":27},{"nctId":"NCT04912765","phase":"PHASE2","title":"Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2021-04-15","conditions":"Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer","enrollment":60},{"nctId":"NCT02159495","phase":"PHASE1","title":"Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2015-12-15","conditions":"Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia","enrollment":31},{"nctId":"NCT05834296","phase":"PHASE1, PHASE2","title":"Study in Subjects With Mild-to-Moderate Alzheimer's Dementia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alzamend Neuro, Inc.","startDate":"2023-07-05","conditions":"Alzheimer Disease","enrollment":30},{"nctId":"NCT01863108","phase":"PHASE1","title":"Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2013-06","conditions":"Melanoma, Tumor Vaccines, Effects of Immunotherapy","enrollment":9},{"nctId":"NCT04963413","phase":"PHASE1","title":"RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.","status":"TERMINATED","sponsor":"University of Florida","startDate":"2022-01-13","conditions":"Glioblastoma","enrollment":6},{"nctId":"NCT06195618","phase":"PHASE1","title":"Personalized Vaccine for TNBC Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Universidad Nacional de Colombia","startDate":"2025-08-01","conditions":"Breast Cancer Female","enrollment":8},{"nctId":"NCT03186118","phase":"PHASE1","title":"Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2017-08-04","conditions":"CD 19+ Acute Leukemia","enrollment":30},{"nctId":"NCT04157127","phase":"PHASE1","title":"Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2020-08-03","conditions":"Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenosquamous Carcinoma","enrollment":18},{"nctId":"NCT04078269","phase":"PHASE1","title":"MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2019-08-26","conditions":"Non-small Cell Lung Cancer","enrollment":6},{"nctId":"NCT02649829","phase":"PHASE1, PHASE2","title":"Autologous Dendritic Cell Vaccination in Mesothelioma","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2017-10-03","conditions":"Malignant Pleural Mesothelioma","enrollment":28},{"nctId":"NCT01885702","phase":"PHASE1, PHASE2","title":"Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2010-10","conditions":"Colorectal Cancer","enrollment":25},{"nctId":"NCT06749925","phase":"PHASE3","title":"Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01","conditions":"Glioblastoma","enrollment":186},{"nctId":"NCT03138161","phase":"PHASE1, PHASE2","title":"SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Sarcoma Oncology Research Center, LLC","startDate":"2017-04-13","conditions":"Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma","enrollment":250},{"nctId":"NCT05539365","phase":"PHASE2","title":"Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"Roswell Park Cancer Institute","startDate":"2025-02-01","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":""},{"nctId":"NCT06522919","phase":"PHASE2","title":"Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-01-07","conditions":"Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer","enrollment":36},{"nctId":"NCT00965224","phase":"PHASE2","title":"Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma","status":"COMPLETED","sponsor":"Zwi Berneman","startDate":"2010-01","conditions":"Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Multiple Myeloma","enrollment":38},{"nctId":"NCT03395587","phase":"PHASE2","title":"Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2018-03-06","conditions":"Glioblastoma","enrollment":136},{"nctId":"NCT06675201","phase":"PHASE2","title":"Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-10-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine, Immune Checkpoint Inhibitors (ICIs)","enrollment":165},{"nctId":"NCT03686683","phase":"PHASE3","title":"Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer","status":"COMPLETED","sponsor":"Dendreon","startDate":"2018-10-18","conditions":"Adenocarcinoma of the Prostate","enrollment":532},{"nctId":"NCT02649582","phase":"PHASE1, PHASE2","title":"Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2015-12","conditions":"Glioblastoma Multiforme of Brain","enrollment":20},{"nctId":"NCT06471673","phase":"PHASE1, PHASE2","title":"A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2024-05-29","conditions":"Breast Cancer, Breast Tumor, Cancer of Breast","enrollment":18},{"nctId":"NCT03371485","phase":"PHASE1","title":"AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Cancer Research UK","startDate":"2018-05-29","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":9},{"nctId":"NCT02061423","phase":"PHASE1","title":"HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2014-04-08","conditions":"Breast Cancer","enrollment":7},{"nctId":"NCT01657734","phase":"","title":"Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2011-09","conditions":"Malignant Gliomas","enrollment":30},{"nctId":"NCT05765084","phase":"PHASE1, PHASE2","title":"Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-02-24","conditions":"Malignant Pleural Mesothelioma","enrollment":15},{"nctId":"NCT04911621","phase":"PHASE1, PHASE2","title":"Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2021-09-10","conditions":"High Grade Glioma, Diffuse Intrinsic Pontine Glioma","enrollment":10},{"nctId":"NCT03927222","phase":"PHASE2","title":"Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma","status":"TERMINATED","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","startDate":"2019-09-30","conditions":"Glioblastoma","enrollment":6},{"nctId":"NCT03548571","phase":"PHASE2, PHASE3","title":"Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2018-04-26","conditions":"Glioblastoma","enrollment":60},{"nctId":"NCT06329908","phase":"EARLY_PHASE1","title":"DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs","status":"RECRUITING","sponsor":"Zhen-Yu Ding","startDate":"2023-09-27","conditions":"Lung Cancer","enrollment":20},{"nctId":"NCT03291444","phase":"PHASE1","title":"CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2018-05-05","conditions":"Leukemia, Acute Lymphocytic (ALL), Leukemia, Acute Myelogenous (AML), Myelodysplastic Syndromes","enrollment":30},{"nctId":"NCT05357898","phase":"PHASE1, PHASE2","title":"Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"SQZ Biotechnologies","startDate":"2022-03-24","conditions":"Adult Solid Tumor","enrollment":20},{"nctId":"NCT01884168","phase":"","title":"Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-03","conditions":"Malignant Tumor","enrollment":30},{"nctId":"NCT03360630","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2016-11-01","conditions":"Lung Cancer, Neoplasms","enrollment":60},{"nctId":"NCT03610360","phase":"PHASE2, PHASE3","title":"DENdritic Cell Immunotherapy for Mesothelioma","status":"COMPLETED","sponsor":"Amphera BV","startDate":"2018-06-21","conditions":"Mesothelioma","enrollment":176},{"nctId":"NCT04212377","phase":"PHASE2","title":"Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2019-04-08","conditions":"Endometrial Cancer","enrollment":8},{"nctId":"NCT04552886","phase":"PHASE1","title":"Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma","status":"COMPLETED","sponsor":"The Cooper Health System","startDate":"2021-10-11","conditions":"Glioblastoma","enrollment":17},{"nctId":"NCT05955157","phase":"PHASE2, PHASE3","title":"Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2023-01-03","conditions":"Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor","enrollment":52},{"nctId":"NCT06193733","phase":"PHASE2","title":"Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection-phase II Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2024-02-19","conditions":"Hepatocellular Carcinoma","enrollment":74},{"nctId":"NCT00849290","phase":"PHASE2","title":"Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)","status":"COMPLETED","sponsor":"Dendreon","startDate":"2004-04","conditions":"Metastatic Androgen Independent Prostate Cancer","enrollment":113},{"nctId":"NCT03450122","phase":"PHASE1","title":"Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-09-13","conditions":"HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma","enrollment":15},{"nctId":"NCT05650918","phase":"PHASE1","title":"MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)","status":"COMPLETED","sponsor":"Joachim Aerts, MD PhD","startDate":"2021-08-30","conditions":"Metastatic Pancreatic Cancer","enrollment":22},{"nctId":"NCT00014131","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients With Kidney Cancer","status":"TERMINATED","sponsor":"Lisata Therapeutics, Inc.","startDate":"2001-11","conditions":"Kidney Cancer","enrollment":9},{"nctId":"NCT04203901","phase":"PHASE2","title":"Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma","status":"TERMINATED","sponsor":"CoImmune","startDate":"2020-07-22","conditions":"Advanced Renal Cell Carcinoma","enrollment":16},{"nctId":"NCT05767684","phase":"PHASE1","title":"Neoantigen Derived DCs as Cancer Treatment","status":"RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2023-06-01","conditions":"Refractory Tumor, Solid Tumor","enrollment":12},{"nctId":"NCT03803397","phase":"PHASE1","title":"Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma","status":"UNKNOWN","sponsor":"PrimeVax Immuno-Oncology Inc.","startDate":"2024-04-01","conditions":"Metastatic Melanoma","enrollment":10},{"nctId":"NCT04084951","phase":"PHASE1","title":"Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"SQZ Biotechnologies","startDate":"2020-01-28","conditions":"Adult Solid Tumor","enrollment":30},{"nctId":"NCT03406715","phase":"PHASE2","title":"Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-03-15","conditions":"Small Cell Lung Cancer, Lung Cancer, Relapsed Small Cell Lung Cancer","enrollment":14},{"nctId":"NCT05786937","phase":"PHASE1","title":"Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-06","conditions":"HIV Vaccine","enrollment":30},{"nctId":"NCT00639639","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Gary Archer Ph.D.","startDate":"2006-02-06","conditions":"Malignant Neoplasms of Brain","enrollment":42},{"nctId":"NCT04615845","phase":"PHASE1","title":"Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC)","status":"TERMINATED","sponsor":"Pharmicell Co., Ltd.","startDate":"2021-06-21","conditions":"Castration Resistant Prostate Cancer, CRPC","enrollment":3},{"nctId":"NCT04614051","phase":"PHASE1","title":"Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC)","status":"TERMINATED","sponsor":"Pharmicell Co., Ltd.","startDate":"2021-03-30","conditions":"Ovarian Cancer","enrollment":2},{"nctId":"NCT03697707","phase":"PHASE2","title":"Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia","status":"UNKNOWN","sponsor":"Mendus","startDate":"2018-10-15","conditions":"Acute Myeloid Leukemia in Remission","enrollment":20},{"nctId":"NCT02334735","phase":"PHASE2","title":"A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence","status":"COMPLETED","sponsor":"Nina Bhardwaj","startDate":"2015-07-01","conditions":"Melanoma","enrollment":36},{"nctId":"NCT04105582","phase":"PHASE1","title":"Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells","status":"COMPLETED","sponsor":"Universidad Nacional de Colombia","startDate":"2019-08-01","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":5},{"nctId":"NCT00045968","phase":"PHASE3","title":"Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer","status":"UNKNOWN","sponsor":"Northwest Biotherapeutics","startDate":"2006-12","conditions":"Glioblastoma Multiforme, Glioblastoma, GBM","enrollment":348},{"nctId":"NCT02662634","phase":"PHASE2","title":"A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"GU Research Network, LLC","startDate":"2016-03","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":""},{"nctId":"NCT03735290","phase":"PHASE1","title":"A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer","status":"TERMINATED","sponsor":"Mendus","startDate":"2019-01-14","conditions":"Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":21},{"nctId":"NCT05270720","phase":"PHASE1","title":"Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer","status":"UNKNOWN","sponsor":"West China Second University Hospital","startDate":"2022-09-01","conditions":"Recurrent Ovarian Cancer","enrollment":9},{"nctId":"NCT03905902","phase":"PHASE3","title":"DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma","status":"WITHDRAWN","sponsor":"SOTIO a.s.","startDate":"2021-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma","enrollment":""},{"nctId":"NCT02010606","phase":"PHASE1","title":"Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2014-01-08","conditions":"Glioblastoma, Glioblastoma Multiforme, Glioma","enrollment":39},{"nctId":"NCT02574377","phase":"PHASE1, PHASE2","title":"myDC/pDC in Stage III Melanoma Patients","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-09","conditions":"Melanoma","enrollment":30},{"nctId":"NCT04999943","phase":"PHASE1","title":"Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2021-07-01","conditions":"Myelodysplastic Syndromes, Dendritic Cell, Hypomethylating Agents","enrollment":40},{"nctId":"NCT04879888","phase":"PHASE1","title":"Personalized Vaccine for Cancer Immunotherapy","status":"COMPLETED","sponsor":"Universidad Nacional de Colombia","startDate":"2016-08","conditions":"Breast Cancer Female","enrollment":9},{"nctId":"NCT04834544","phase":"PHASE2","title":"A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2021-04-19","conditions":"Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma","enrollment":75},{"nctId":"NCT03657966","phase":"PHASE2","title":"DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer","status":"COMPLETED","sponsor":"SOTIO a.s.","startDate":"2017-11-23","conditions":"Ovarian Cancer Recurrent","enrollment":33},{"nctId":"NCT04082182","phase":"PHASE1","title":"MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"University Hospital, Ghent","startDate":"2019-08-26","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":7},{"nctId":"NCT00626483","phase":"PHASE1","title":"Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia","status":"COMPLETED","sponsor":"Gary Archer Ph.D.","startDate":"2007-04-24","conditions":"Malignant Neoplasms Brain","enrollment":34},{"nctId":"NCT02677155","phase":"PHASE2","title":"Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2016-01","conditions":"Follicular Lymphoma","enrollment":10},{"nctId":"NCT02661685","phase":"PHASE1","title":"Safety Study of Adoptive Transfer of Autologous IKDC-like Cells","status":"COMPLETED","sponsor":"National Defense Medical Center, Taiwan","startDate":"2016-05","conditions":"Neoplasm Metastasis","enrollment":6},{"nctId":"NCT03083054","phase":"PHASE1, PHASE2","title":"Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"University of Campinas, Brazil","startDate":"2016-08","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia","enrollment":5},{"nctId":"NCT01567202","phase":"PHASE2","title":"Study of DC Vaccination Against Glioblastoma","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2012-03","conditions":"Glioma, Glioblastoma Multiforme, Neoplasms","enrollment":100},{"nctId":"NCT00107185","phase":"PHASE1","title":"Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2005-01","conditions":"Brain and Central Nervous System Tumors","enrollment":7},{"nctId":"NCT00068510","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients With Malignant Glioma","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2003-06","conditions":"Brain and Central Nervous System Tumors","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":150,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Immunotherapy Nusantara","Dendritic Cell vaccine","DCVax-L","DCVax","DCVax-Brain"],"phase":"phase_3","status":"active","brandName":"Dendritic cell immunotherapy","genericName":"Dendritic cell immunotherapy","companyName":"PT. JES Kasih Nusantara Sejahterah","companyId":"pt-jes-kasih-nusantara-sejahterah","modality":"Biologic","firstApprovalDate":"","aiSummary":"Dendritic cell immunotherapy activates the patient's own dendritic cells to present tumor antigens and stimulate a cytotoxic T-cell response against cancer cells. Used for Cancer (specific indication not publicly detailed for this investigational product).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}